Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid
Advanced Healthcare Materials · 2024-12 · 13 (30)
DOI: 10.1002/adhm.202401936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 09.10.2024. Verfasst von Zeynab Nosrati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada. Hauptthemen laut MEDLINE: Prodrugs, Methotrexate, Synovial Fluid, Arthritis, Rheumatoid. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of British Columbia, Canada Foundation for Innovation, Lundbeck Foundation.
Abstract (Originalsprache)
Many patients cannot tolerate low‐dose weekly methotrexate (MTX) therapy for inflammatory arthritis treatment due to life‐threatening toxicity. Although biologics offer a target‐specific therapy, it raises the risk of serious infections and even cancer due to immune system suppression. We introduce an anti‐inflammatory arthritis MTX ester prodrug using a long‐circulating biocompatible polymeric macromolecule: folic acid (FA) functionalized hyperbranched polyglycerol (HPG). In vitro the drug MTX is incrementally released through pH and enzymatic degradation over 2 weeks. The role of matrix metalloproteinases (MMPs) in site‐specific prodrug activation was verified using synovial fluid (SF) of 26 rheumatology patients and 4 healthy controls. Elevated levels of specific MMPs‐markers of joint inflammation‐positively correlated with enhanced prodrug release explained by acid‐catalyzed hydrolysis of esters by proteases. Intravenously administered 111 In‐radiolabeled prodrug confirmed by SPECT/CT imaging that it accumulated preferentially in inflamed joints while reducing off‐target side‐effects in a mouse model of rheumatoid arthritis (RA). Added FA as a targeting vector prolonged prodrug action; prodrug with 4x less MTX applied every 2 weeks was as effective as weekly MTX therapy. The preclinical results suggest a prodrug‐based strategy for the treatment of inflammatory joint diseases, with potential for other chronic inflammatory diseases and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.
- Department of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.
- Burnaby Medical and Surgical Specialists, Burnaby, BC, V3J 1M2, Canada.
- Polaris Rheumatology, Vancouver, BC, V5Z 1H2, Canada.
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark, 2100.
ORCID-Profile: Zeynab Nosrati, Marta Bergamo, Cristina Rodríguez-Rodríguez, Jonathan Chan, Kam Shojania, Raheem B Kherani, Katayoun Saatchi, Urs O Häfeli
Förderung
- University of British Columbia
- Canada Foundation for Innovation
- Lundbeck Foundation
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Nosrati, Z., Chen, Y. A., Bergamo, M., Rodríguez-Rodríguez, C., Chan, J., Shojania, K., Kherani, R. B., Chin, C., Kelsall, J. T., Dehghan, N., Colwill, A. M., Collins, D., Saatchi, K., & Häfeli, U. O. (2024). Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid. Advanced Healthcare Materials, 13(30). https://doi.org/10.1002/adhm.202401936
Vancouver
Nosrati Z, Chen YA, Bergamo M, Rodríguez-Rodríguez C, Chan J, Shojania K, et al. Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid. Advanced Healthcare Materials. 2024;13(30). doi:10.1002/adhm.202401936
BibTeX
@article{Nosrati2024,
author = {Nosrati, Zeynab and Chen, Yun An and Bergamo, Marta and Rodríguez-Rodríguez, Cristina and Chan, Jonathan and Shojania, Kam and Kherani, Raheem B and Chin, Carson and Kelsall, John T and Dehghan, Natasha and Colwill, Ann Marie and Collins, David and Saatchi, Katayoun and Häfeli, Urs O},
title = {Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {30},
doi = {10.1002/adhm.202401936}
}
EUVIMED